GlassScriptPhysician profile
Meriam Khan
NPI 1194381582
$773.63
in general payments reported to CMS, 2019-2025
13 companies · $573 in 2025
The $573 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.01 · 2022: $30.43 · 2023: $28.40 · 2024: $124 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $169.90 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $134.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.05 | 2022-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $65.79 | 2023-2025 | Shingrix, Bexsero |
| Dexcom, INC. | $65.71 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $63.20 | 2025 | Rybelsus, Ozempic, Wegovy |
| Jazz Pharmaceuticals INC. | $55.02 | 2025 | |
| Exact Sciences Corporation | $41.51 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $32.74 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.85 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $13.94 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $13.70 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $12.27 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meriam Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.